Substantial Trade Secret Verdicts Continue with $452 Million Decision Against South Korean Company
US civil juries have returned a number of substantial trade secret verdicts against defendants over the past decade. In December 2024, a company from South Korea became the most recent defendant on the receiving end of a large trade secret jury verdict.
The lawsuit was brought by a company called Insulet. The case was filed on August 2, 2023 in the United States District Court for the District of Massachusetts and assigned case number 23-11780-FDS. The dispute involved information regarding the design, manufacturing process, and functionality of an insulin delivery system marketed by Insulet under the name Omnipod. The complaint filed by Insulet identified the product at issue as “Insulet’s first-of-its-kind ‘patch pump,’ a compact, wearable, waterproof, adhesive medical device that delivers insulin to people with insulin-dependent diabetes.” The complaint alleged that more than $600 million was invested in nearly two decades of work to bring Insulet’s product to market, whereas defendant EOFlow’s product was brought to market in South Korea in just five years, after EOFlow hired former employees of Insulet and gained access to trade secret information.
The case received media attention previously after a preliminary injunction was entered by the District Court, but the injunction was then reversed by the US Court of Appeals for the Federal Circuit in a sternly worded decision.
In December 2024, after a lengthy trial, the Massachusetts jury concluded that corporate defendants EOFlow, Inc., EOFlow Co., Ltd., and Nephria Bio, Inc., along with three individuals, misappropriated multiple trade secrets of Insulet. According to Insulet’s counsel, the jury awarded Insulet $170 million in compensatory damages and “also found that the misappropriation of three of Insulet’s trade secrets was willful and malicious and awarded an additional $282 million in exemplary or punitive damages, for a total damages award of $452 million.”
This article is available in the Jenner & Block Japan Newsletter. / この記事はJenner & Blockニュースレターに掲載されています。
Related Lawyers
Related Articles
Related Capabilities
© 2026 Jenner & Block LLP. Attorney Advertising. Jenner & Block LLP is an Illinois Limited Liability Partnership including professional corporations. This publication, presentation, or event is not intended to provide legal advice but to provide information on legal matters and/or firm news of interest to our clients and colleagues. Readers or attendees should seek specific legal advice before taking any action with respect to matters mentioned in this publication or at this event. The attorney responsible for this communication is Brent E. Kidwell, Jenner & Block LLP, 353 N. Clark Street, Chicago, IL 60654-3456. Prior results do not guarantee a similar outcome. Jenner & Block London LLP, an affiliate of Jenner & Block LLP, is a limited liability partnership established under the laws of the State of Delaware, USA and is authorised and regulated by the Solicitors Regulation Authority with SRA number 615729. Information regarding the data we collect and the rights you have over your data can be found in our Privacy Notice. For further inquiries, please contact dataprotection@jenner.com.
US civil juries have returned a number of substantial trade secret verdicts against defendants over the past decade. In December 2024, a company from South Korea became the most recent defendant on the receiving end of a large trade secret jury verdict.
The lawsuit was brought by a company called Insulet. The case was filed on August 2, 2023 in the United States District Court for the District of Massachusetts and assigned case number 23-11780-FDS. The dispute involved information regarding the design, manufacturing process, and functionality of an insulin delivery system marketed by Insulet under the name Omnipod. The complaint filed by Insulet identified the product at issue as “Insulet’s first-of-its-kind ‘patch pump,’ a compact, wearable, waterproof, adhesive medical device that delivers insulin to people with insulin-dependent diabetes.” The complaint alleged that more than $600 million was invested in nearly two decades of work to bring Insulet’s product to market, whereas defendant EOFlow’s product was brought to market in South Korea in just five years, after EOFlow hired former employees of Insulet and gained access to trade secret information.
The case received media attention previously after a preliminary injunction was entered by the District Court, but the injunction was then reversed by the US Court of Appeals for the Federal Circuit in a sternly worded decision.
In December 2024, after a lengthy trial, the Massachusetts jury concluded that corporate defendants EOFlow, Inc., EOFlow Co., Ltd., and Nephria Bio, Inc., along with three individuals, misappropriated multiple trade secrets of Insulet. According to Insulet’s counsel, the jury awarded Insulet $170 million in compensatory damages and “also found that the misappropriation of three of Insulet’s trade secrets was willful and malicious and awarded an additional $282 million in exemplary or punitive damages, for a total damages award of $452 million.”
This article is available in the Jenner & Block Japan Newsletter. / この記事はJenner & Blockニュースレターに掲載されています。
Related Lawyers
Related Articles
Related Capabilities
© 2026 Jenner & Block LLP. Attorney Advertising. Jenner & Block LLP is an Illinois Limited Liability Partnership including professional corporations. This publication, presentation, or event is not intended to provide legal advice but to provide information on legal matters and/or firm news of interest to our clients and colleagues. Readers or attendees should seek specific legal advice before taking any action with respect to matters mentioned in this publication or at this event. The attorney responsible for this communication is Brent E. Kidwell, Jenner & Block LLP, 353 N. Clark Street, Chicago, IL 60654-3456. Prior results do not guarantee a similar outcome. Jenner & Block London LLP, an affiliate of Jenner & Block LLP, is a limited liability partnership established under the laws of the State of Delaware, USA and is authorised and regulated by the Solicitors Regulation Authority with SRA number 615729. Information regarding the data we collect and the rights you have over your data can be found in our Privacy Notice. For further inquiries, please contact dataprotection@jenner.com.
News and Insights
Publications
From Four Remedies to Multiple Pressures: The New Risk Model for Government Contractors and Grantees, Government Contractor
Partners David Robbins, Emily Loeb, and Matthew Haws and Associate Rachel Palermo authored an article for Government Contractor examining how the oversight landscape is changing for government contractors, grant recipients, universities, and nonprofits, and what general counsel and boards should do in response.
November 18, 2026
Publications
In The American Lawyer, “My Client Is Often the Truth”: Neil Barofsky on What Matters Most
Partner Neil Barofsky, who was a finalist for Attorney of the Year at the publication’s 2026 Industry Awards, was profiled in The American Lawyer. The article examines what independence requires of a monitor or ombudsperson who oversees reforms after things have gone wrong and how that commitment has shaped his work.
November 16, 2026
Publications
New York Court Allows Attorney General’s Zelle Fraud Lawsuit to Proceed, In New York Law Journal
Partners Jeremy Creelan, Megan Poetzel, Laurel Loomis Rimon, and Michael Ross and Associate Julian Buff authored an article for the New York Law Journal examining a recent New York trial court decision allowing the New York Office of the Attorney General’s (OAG) lawsuit against Early Warning Services, LLC, the owner of the payment service Zelle, to proceed to discovery.
November 16, 2026
News
In Billboard, Partner Precious Jacobs Discusses the Rise in Artist-Manager Litigation
Partner Precious S. Jacobs was featured in Billboard in “It’s Not Just Timbaland: Why Are So Many Artists Suing Their Managers Right Now?.” The article examines the recent wave of lawsuits between music artists and their managers and why that relationship is so prone to conflict.
November 12, 2026
Event
Partner Terri Mascherin to Speak at Illinois State Bar Association Seminar on Negotiation Ethics
On November 11, Partner Terri Mascherin will join a faculty panel for the Illinois State Bar Association (ISBA) continuing legal education (CLE) seminar “Negotiation Ethics: Winning Without Selling Your Soul.”
November 11, 2026
Publications
Partner Emily Loeb Discusses Congressional Oversight Preparedness in The Washington Post’s Health Brief
Partner Emily Loeb, co-chair of Jenner & Block’s Congressional Investigations Practice, was quoted in The Washington Post’s Health Brief article examining how the 2026 midterm election results may reshape the health care policy landscape and the industry’s relationship with Washington.
November 10, 2026